-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FOR-46 in Relapsed Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FOR-46 in Relapsed Multiple Myeloma Drug Details: FOR-46 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NG-348 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NG-348 in Solid Tumor Drug Details: NG-348 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNC-210 in Anxiety Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BNC-210 in Anxiety DisordersDrug Details:BNC-210 (IW-2143) is under development for the treatment of agitation (anxiety disorder),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNC-210 in Post-Traumatic Stress Disorder (PTSD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BNC-210 in Post-Traumatic Stress Disorder (PTSD)Drug Details:BNC-210 (IW-2143) is under development for the treatment of agitation...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNC-210 in Social Anxiety Disorder (SAD/Social Phobia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BNC-210 in Social Anxiety Disorder (SAD/Social Phobia)Drug Details:BNC-210 (IW-2143) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sugemalimab in Natural Killer Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sugemalimab in Natural Killer Cell Lymphomas Drug Details: Sugemalimab (Cejemly) is an recombinant human anti-PD-L1...
-
Product Insights
![]()
Post-Traumatic Stress Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Traumatic Stress Disorder (PTSD) Clinical Trials Market Report Overview The PTSD clinical trial market research report provides an overview of PTSD clinical trials scenario. This report provides top line data relating to the clinical trials on PTSD. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The...
-
Product Insights
![]()
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. The Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline drugs market research report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active...
-
Product Insights
![]()
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
![]()
Net Present Value Model: BNC-210
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BNC-210 Drug Details BNC-210 (IW-2143) is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.